Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Suzi Apu (also known as Suzi Afu) is a traditional Uyghur medicine formulated as an oral tablet, primarily indicated for the treatment of vitiligo and other conditions such as arteriosclerosis and coronary heart disease. It is a multi-herb botanical mixture consisting of Cymbopogon distans (芸香草), Arnebia euchroma (紫草), and Artemisia absinthium (苦艾). Suzi Apu is designed to promote melanin synthesis, improve microcirculation, and increase skin pigmentation. The drug is approved in China and manufactured by Shaanxi Junbisha Pharmaceutical. Additionally, Xinjiang Yinduolan Pharmaceutical (formerly Xinjiang Huakang Pharmaceutical) is developing a Class 4 traditional Chinese medicine formulation of Suzi Apu tablets, which is currently undergoing Phase 3 clinical evaluation for non-segmental (common-type) vitiligo.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Suzi Apu.